The updated (2022) ESC/ERS (European Society of Cardiology/European Respiratory Society) guidelines provide new definitions of pulmonary hypertension (PH) with lowered diagnostic thresholds, as well as revised treatment algorithms based on risk stratification at diagnosis and follow-up. Findings from the multicenter INCREASE study of inhaled treprostinil, and the phase 3 STELLAR trial of sotatercept, provide new evidence for the use of these agents in particular patients with PH. How actionable are the data supporting these changes? How is implementing them expected to improve patient outcomes? And all in all, what do these developments mean to the practicing pulmonologist?
These are some of the questions addressed by Catherine Simpson MD, MHS, and Darin Rosen, MD, from the Division of Pulmonary and Critical Care at Johns Hopkins School of Medicine, in this issue of ePulmonology Review.
Assistant Professor of Medicine,
Division of Pulmonary and Critical Care,
Johns Hopkins School of Medicine
Johns Hopkins University
Professor of Medicine, Epidemiology and Environmental Health Sciences
Johns Hopkins University School of Medicine
Senior Clinic Nurse Coordinator
Johns Hopkins Medicine
1.0 hour Physicians
1.0 contact hour Nurses
Launch date: January 31, 2024
Expiration date: January 30, 2026